You are here: Industry Insights > ADC

News List

Emergence Therapeutics Closes €87 Million Series A Financing Round contractpharma
December 08, 2021
Plans to advance its Nectin-4 antibody drug conjugate.
Abzena, BiVictriX Therapeutics Collaborate to Manufacture ADCs ContractPharma
November 19, 2021
BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience...
SOTIO, LegoChem Biosciences Enter ADC License Agreement ContractPharma
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company, entered an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc., a biotechnology company...
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences B3Cnewswire
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc...
MilliporeSigma Launches New Tech and Expanded ADC Capacity ContractPharma
October 29, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, has launched new technology and expanded capacity to advance ADC therapies.
NEWS SEC-MS: a “powerful tool” for ADC analysis, find researchers EuropeanPharmaceuticalReview
October 28, 2021
In a new study, scientists demonstrated that size exclusion chromatography (SEC) could be successfully combined with mass spectrometry (MS) to characterise antibody-drug conjugates (ADCs) on the intact molecular level.
CStone presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 prnasia
October 13, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
Lonza Extends Collaboration for Monoclonal Antibody Supply at Scale americanpharmaceuticalreview
July 19, 2021
Lonza, a CDMO partner to the biopharma industry, announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies, under a long-term agreement.
Lonza extends collaboration with biopharma client for antibody drug conjugate supply expresspharma
July 19, 2021
Lonza Group has extended collaboration with a major biopharma industry client for the supply of an antibody drug conjugate (ADC) against hard-to-treat cancers, the company said in a statement.
Novasep, Exelixis Ink ADC Manufacturing Agreement contractpharma
July 07, 2021
Covers the cGMP clinical manufacturing of a next-generation ADC drug candidate.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page